Brief: Magenta Therapeutics Provides Update For Mgta-117 Phase 1/2 Dose Escalation Clinical Trial

Dianthus Therapeutics

20/12/2022 14:03

Dec 20 (Reuters) - Magenta Therapeutics Inc  MGTA.O :
    * MAGENTA THERAPEUTICS PROVIDES UPDATE FOR MGTA-117 PHASE
1/2 DOSE
ESCALATION CLINICAL TRIAL
    * COHORT 4 DOSING STOPPED PER CLINICAL TRIAL PROTOCOL DUE TO
DOSE-LIMITING TOXICITIES
    * COHORT 4 DOSING STOPPED PER CLINICAL TRIAL PROTOCOL DUE TO
DOSE-LIMITING TOXICITIES
    * PLAN TO DOSE ADDITIONAL PARTICIPANTS IN COHORT 3 PER
CLINICAL
TRIAL PROTOCOL
    * 3 PARTICIPANTS HAVE BEEN DOSED IN COHORT 4, DOSE-LIMITING
TOXICITIES WERE OBSERVED IN SECOND AND THIRD DOSED PARTICIPANTS
    * ON DEC 15, RECEIVED A REPORT OF A RESPIRATORY SAE FOR
THIRD
DOSED PARTICIPANT
    * REPORTED CLINICAL DATA AND OTHER INFORMATION APPLICABLE TO
FIRST
OBSERVED DLT TO U.S. FDA ON DEC 20

Source text for Eikon:  ID:nGNX8fR28L 
Further company coverage:  MGTA.O 
 ((Reuters.Briefs@thomsonreuters.com))